Hepatocellular Carcinoma (HCC)CirrhosisRisk Prediction for Liver CancerEpigenomics
Investigational drug(s) / intervention(s)
Circulating mSEPT9 Biomarker Testing
Circulating mSEPT9 Biomarker Testing: This intervention involves the analysis of the circulating epigenetic biomarker mSEPT9 through plasma samples collected from patients with cirrhosis. The mSEPT9 test evaluates the methylation status of the SEPT9 gene promoter using a triplicate assay. A "switch" in the test status, defined as a transition from triple-negative (no methylation detected in any triplicate) to at least one positive triplicate, is being investigated as a prognostic marker for the development of hepatocellular carcinoma (HCC).
The mSEPT9 test is conducted on plasma samples collected during routine blood draws at each of the 11 scheduled study visits. Samples are processed and analyzed in batches using specialized high-throughput equipment provided by Epigenomics/New Day Diagnostics. Results of the mSEPT9 test are not shared with clinicians during the study period to avoid influencing patient management, ensuring the test is purely investigational in this context.
Study summary
This study aims to evaluate the role of the circulating epigenetic biomarker mSEPT9 in predicting the risk of hepatocellular carcinoma (HCC) in patients with cirrhosis. HCC is a primary liver cancer that frequently develops in individuals with cirrhosis, and early detection is critical for improving outcomes. This research involves 400 patients with cirrhosis who will be followed every six months for up to 60 months. During these visits, blood samples will be collected to analyze mSEPT9 levels. By identifying changes in this biomarker, the study seeks to improve early diagnosis and personalize surveillance strategies, potentially enhancing patient survival and quality of life.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Adults aged 18 years or older.
* Patients diagnosed with cirrhosis confirmed by clinical, biochemical, radiological, or histological criteria.
* Cirrhosis attributable to one or more of the following etiologies: alcohol, hepatitis C (HCV), hepatitis B (HBV), nonalcoholic steatohepatitis (NASH), hemochromatosis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, or cryptogenic causes.
* Patients actively followed in one of the participating study centers.
* Patients affiliated with a social security program or equivalent.
* Patients with a body weight greater than 45 kg.
* Patients who have been fully informed about the study procedures and have provided oral informed consent.
Exclusion Criteria:
* History of hepatocellular carcinoma (HCC).
* History of any other primary or secondary malignant liver tumor.
* Diagnosis of malignancy or hematologic disorders within the past 5 years (without time limitation for hematologic malignancies).
* Patients currently undergoing hemodialysis.
* Pregnant or breastfeeding women.
* Individuals under legal protection (e.g., guardianship, curatorship) or unable to provide consent.
* Minors or individuals younger than 18 years.
* Individuals deprived of liberty by judicial or administrative order.
* Patients with psychiatric conditions receiving care under legal constraints (e.g., articles L.3212-1 and L.3213-1).
* Patients unable to comply with the study protocol requirements.
Primary outcome measure(s)
Association Between mSEPT9 Test Switch and Hepatocellular Carcinoma (HCC) Development — Annually for up to 60 months or until the occurrence of HCC, whichever occurs first. Evaluate the relationship between a 'switch' in the mSEPT9 test result-defined as a transition from triple-negative (no methylation detected across all triplicates) to at least one positive triplicate-and the occurrence of hepatocellular carcinoma (HCC), as diagnosed using international criteria established by the AASLD.
Trial sites (1)
Facility
City
Region
Status
Regional and University Hospital Center of Nancy
Vandœuvre-lès-Nancy
France
Recruiting
More Central Hospital, Nancy, France trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
